Atea Pharmaceuticals
IPOCommitted to the discovery, development and commercialization of oral direct-acting antiviral therapies.
- Headquarters
- Boston, Massachusetts
- Employees
- 51–200
- Founded
- 2014
- Business Model
- B2B
- Website
- ateapharma.com
- Total Funding
- $215.0M
- Last Round
- $215.0M Series DMay 2020
- Rounds
- 1
- Type
- Public
About
Atea Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing oral direct-acting antiviral therapies for serious viral diseases with unmet medical needs. Its lead program is a fixed-dose combination of bemnifosbuvir and ruzasvir in Phase 3 development for hepatitis C virus, with topline data from the C-BEYOND trial expected mid-2026. Atea also has early-stage programs targeting dengue and RSV.
Tech & App Stack
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingSign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Investors
Sign up to view investors
Create a free account to see which investors have funded this company.
Create Free AccountSimilar Companies
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
World-leading Canadian cannabis company cultivating and selling medicinal and recreational cannab...
Biopharmaceutical services company
Specialty pharmaceutical company
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...